Biogen Inc. (NASDAQ:BIIB) named Daniel Karp EVP of corporate development, effective June 11. The company said he will lead corporate and business development and corporate strategy.
Karp was VP of worldwide business development and head of business development for R&D at Pfizer Inc. (NYSE:PFE).
He will report to Biogen CEO Michel Vounatsos.
In June 2016, Biogen EVP of Strategy and Business Development Adam Koppel left the company and returned to Bain Capital. He had led the biotech's business development activities since EVP of Corporate Development Steven Holtzman departed in March 2016. At the time of Koppel's departure, Biogen it did not plan to fill his role.
Biogen was up $0.57 to $294.97 in afternoon trading Thursday.